Summary:
The ALIGN Study for IgA Nephropathy
The ALIGN Study is testing an investigational medication, called atrasentan, that has the potential to reduce the amount of protein in urine and preserve kidney function in patients with IgA nephropathy. If you have IgAN this study may be an option for you.
Who can be in the study?
You may qualify to participate if you:
- Are 18 years of age or older
- Have been diagnosed with IgAN from a biopsy
- Are taking a stable dose of a medication called an ACE inhibitor or ARB or are unable to tolerate ACEi/ARB medication
- Have elevated levels of protein in your urine
- Do not have severe loss of kidney function
- Are willing to use adequate contraception
Ask your doctor about these eligibility criteria and if you may qualify.